Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Código QR

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Bo Ahr&eacute;nDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates insulin secretion and inhibits glucag...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Bo Ahr&eacute;n
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/1553c20b118747d28cd087d966679606
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz B
Publicado: (2013)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto M
Publicado: (2013)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo E, et al.
Publicado: (2013)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Shannon A Miller, et al.
Publicado: (2009)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Jonathan K Reynolds
Publicado: (2009)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto S, et al.
Publicado: (2015)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Radha Andukuri, et al.
Publicado: (2009)

Clinical utility of fixed combinations of sitagliptin&ndash;metformin in treatment of type 2 diabetes
por: Karen Barnard, et al.
Publicado: (2010)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
por: Stolar MW, et al.
Publicado: (2013)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert J
Publicado: (2015)

Sex differences in type 2 diabetes: focus on disease course and outcomes
por: Arnetz L, et al.
Publicado: (2014)

Comorbidity and glycemia control among patients with type 2 diabetes in primary care
por: Catherine Hudon, et al.
Publicado: (2008)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
por: Kim Y, et al.
Publicado: (2012)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser RF, et al.
Publicado: (2013)

Saxagliptin for type 2 diabetes
por: Antonio R Chacra, et al.
Publicado: (2010)

Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes
por: Galina Smushkin, et al.
Publicado: (2009)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz SS, et al.
Publicado: (2016)

Risk factors associated with metabolic syndrome in type 2 diabetes mellitus patients according to World Health Organization, Third Report National Cholesterol Education Program, and International Diabetes Federation definitions
por: Angel Rodr&iacute;guez, et al.
Publicado: (2010)

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
por: MacConell L, et al.
Publicado: (2015)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review
por: Katrine B Hansen, et al.
Publicado: (2010)

Sexual dysfunction in diabetic women: prevalence and differences in type 1 and type 2 diabetes mellitus
por: Mazzilli R, et al.
Publicado: (2015)

Type 2 diabetes in Brazil: epidemiology and management
por: Almeida-Pititto B, et al.
Publicado: (2015)

Metabolic syndrome in hemodialysis patients as a risk factor for new-onset diabetes mellitus after renal transplant: a prospective observational study
por: Bonet J, et al.
Publicado: (2013)

Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
por: Cebeci Z, et al.
Publicado: (2015)

Linking obesity with type 2 diabetes: the role of T-bet
por: Wali JA, et al.
Publicado: (2014)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
por: Rigato M, et al.
Publicado: (2014)

Risk management in the treatment of type 2 diabetes with pioglitazone
por: Giuseppe Derosa, et al.
Publicado: (2009)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
por: Gregory E Peterson
Publicado: (2009)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Pamela Kushner
Publicado: (2010)

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
por: Henri K Parson, et al.
Publicado: (2010)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Joshua J Neumiller, et al.
Publicado: (2010)

Evidence for the benefit of exercise therapy in patients with type 2 diabetes
por: Madden KM
Publicado: (2013)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander PA
Publicado: (2012)

AMPK activation: a therapeutic target for type 2 diabetes?
por: Coughlan KA, et al.
Publicado: (2014)

Red cell distribution width in type 2 diabetic patients
por: Nada AM
Publicado: (2015)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Robert Moses
Publicado: (2009)

Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation
por: Dara P Schuster
Publicado: (2010)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Stanley S Schwartz
Publicado: (2010)